spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  pulmonary arterial hypertension 

 HSMN NewsFeed - 2 Jan 2024
Pulnovo Medical Announces PADN Receives FDA HUD Designation and US CMS Medicare Coverage Code and NMPA Approval
Devices Regulatory FDA Reimbursement
 HSMN NewsFeed - 1 Apr 2021
United Therapeutics Announces FDA Approval and Launch of Tyvaso(R) for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
Biopharmaceuticals FDA Product Launch
 HSMN NewsFeed - 19 Jan 2021
Occlutech's Atrial Flow Regulator (AFR) Receives U.S. FDA Breakthrough Device Designation for Heart Failure (HF)
Devices Cardiology FDA
 HSMN NewsFeed - 18 Dec 2020
Occlutech's Atrial Flow Regulator (AFR) Receives U.S. FDA Breakthrough Device Designation
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 2 Dec 2020
V-Wave Announces Appointment of Bill Hughes as Chief Financial Officer
Devices Interventional Cardiology Personnel
 HSMN NewsFeed - 6 Aug 2020
FDA grants inhaled use IND for RLF-100 (aviptadil) to treat patients with moderate and severe COVID-19 aiming to prevent progression to respiratory failure
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 24 Jul 2020
Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options
Biopharmaceuticals Drug Delivery Regulatory
 HSMN NewsFeed - 8 Jun 2020
Insmed Receives FDA Breakthrough Therapy Designation for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Apr 2020
Insmed Appoints Carol A. Schafer to its Board of Directors
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 16 Mar 2020
ADVANZ PHARMA Corp. Limited to Acquire Specialty Pharmaceutical Company Correvio Pharma Corp.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 16 Mar 2020
ADVANZ PHARMA to Acquire Correvio
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 5 Mar 2020
V-Wave Receives CE Mark for the Ventura(TM) Interatrial Shunt System
Devices Cardiology Regulatory
 HSMN NewsFeed - 30 Jan 2020
Insmed Appoints Sara Bonstein as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jan 2020
Altavant Sciences Acquires Onspira Therapeutics, Adding a Potentially Life-Saving Treatment for Post-Lung Transplant Patients to the Altavant Pipeline
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 24 Dec 2019
Correvio Receives Complete Response Letter From U.S. FDA for Brinavess and Provides Update on Recent Events
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 11 Dec 2019
Correvio Announces Intention to Explore Strategic Alternatives to Maximize Stakeholder Value
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 25 Jul 2019
U.S. FDA Accepts Correvio's Resubmitted New Drug Application For Brinavess (vernakalant)
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 24 Jun 2019
Correvio Resubmits Brinavess (Vernakalant) New Drug Application to U.S. FDA for the Treatment of Patients with Recent Onset Atrial Fibrillation
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 8 Apr 2019
United Therapeutics Announces BEAT Study of Esuberaprost Does Not Meet Primary Endpoint
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 12 Mar 2019
William T. Abraham, MD, joins V-Wave as Chief Medical Officer
Devices Cardiology Personnel
 HSMN NewsFeed - 2 Jan 2019
Altavant Sciences Appoints Lyn Baranowski Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Jan 2019
Correvio Announces Chief Executive Officer Succession Plan and Other Board and Executive Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Oct 2018
FDA Approves KYPROLIS(R) (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Sep 2018
United Therapeutics And MannKind Announce Collaboration For Pulmonary Hypertension Products
Biopharmaceuticals Licensing
 HSMN NewsFeed - 8 Aug 2018
United Therapeutics Announces FREEDOM-EV Study Of Orenitram Meets Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 17 May 2018
Correvio Announces Enrollment of First Patient in Phase 3 Study Evaluating Brinavess(R) in China
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 30 Apr 2018
United Therapeutics To Acquire SteadyMed Ltd.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 17 Apr 2018
Cardiome Completes Enrollment in the Post Approval Safety Study SPECTRUM Evaluating Brinavess(R)
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 16 Feb 2018
Arena Pharmaceuticals Announces Changes to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Jan 2018
Eiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 3 Jan 2018
Corsair Pharma and United Therapeutics Enter into Strategic Collaboration to Advance Novel Treprostinil Prodrugs
Biopharmaceuticals Licensing
 HSMN NewsFeed - 12 Dec 2017
Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 20 Nov 2017
United Therapeutics Announces Additional Six Months Of Regulatory Exclusivity For Adcirca(R)
Biopharmaceuticals FDA Licensing
 HSMN NewsFeed - 23 Oct 2017
United Therapeutics Announces FDA Approval of Third Generation Nebulizer for the Tyvaso(R) Inhalation System
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 12 Sep 2017
Cardiome Announces Agreement with Basilea for Distribution of Zevtera(R)/Mabelio(R) (Ceftobiprole) in Europe and Israel
Biopharmaceuticals Licensing Distribution
 HSMN NewsFeed - 6 Sep 2017
Actelion Receives FDA Approval Of TRACLEER(R) (bosentan) For Use In Pediatric Patients With Pulmonary Arterial Hypertension
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Aug 2017
Cardiome Provides U.S. Regulatory Update For BRINAVESS
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 21 Jun 2017
Cardiome Announces Licensing Agreement for XYDALBA(TM) (Dalbavancin Hydrochloride) to Support Planned Commercialization in Israel
Biopharmaceuticals Licensing
 HSMN NewsFeed - 16 Jun 2017
Johnson & Johnson Announces Completion of Acquisition of Actelion
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 14 Jun 2017
Arena Pharmaceuticals Appoints Jennifer Jarrett to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Jun 2017
Cardiome Announces Commercial Launch of BRINAVESS(R) (Vernakalant Hydrochloride) in Canada
Biopharmaceuticals Cardiology Product Launch
 HSMN NewsFeed - 3 Mar 2017
Cardiome Announces Commercial Launch of Xydalba(TM) (dalbavancin) in France
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 8 Dec 2016
Cardiome Announces Commercial Launch of Xydalba(TM) (dalbavancin) in the UK
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 29 Nov 2016
Cardiome Advances Toward the UK XYDALBA(TM) (dalbavancin) Launch
Biopharmaceuticals Reimbursement Product Launch
 HSMN NewsFeed - 5 Oct 2016
Insmed Announces Worldwide License Agreement with AstraZeneca for Oral DPP1 Inhibitor
Biopharmaceuticals Licensing
 HSMN NewsFeed - 27 Sep 2016
Insmed Appoints Roger Adsett as Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Aug 2016
Arena Pharmaceuticals Announces Appointment of Vincent Aurentz as Chief Business Officer
Biopharmaceuticals Gastroenterology Personnel
 HSMN NewsFeed - 4 Jul 2016
European Commission Approves Extended Indication For Amgen's Kyprolis(R) (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Patients
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 12 May 2016
Cardiome Announces the Launch of ESMOCARD Solution for Injection in France
Biopharmaceuticals Cardiology Product Launch
 HSMN NewsFeed - 9 Nov 2015
Eiger BioPharmaceuticals Announces License Agreement with Nippon Kayaku to Develop Bestatin(TM) (ubenimex) for Inflammatory Diseases Involving LTB4
Biopharmaceuticals Licensing
 HSMN NewsFeed - 15 Sep 2015
Bellerophon Therapeutics Announces Leadership Team Changes
Devices Drug Delivery Personnel
 HSMN NewsFeed - 14 Apr 2015
Eiger BioPharmaceuticals Announces Senior Staff Appointments in Clinical Development and Regulatory Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Mar 2015
Selten Pharma, Inc. Receives Orphan Drug Designation From U.S. FDA for the Treatment of Pulmonary Arterial Hypertension
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Dec 2014
Ascendis Pharma A/S Completes $60 million Oversubscribed Series D Financing
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 10 Feb 2014
Mast Therapeutics Signs Definitive Agreement To Acquire Aires Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 23 Sep 2013
Bayer receives approval for Adempas(R) as first drug to treat rare heart and lung disease
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 Jul 2013
ARCA biopharma Announces Additions to GENETIC-AF Leadership Team
Biopharmaceuticals Cardiology Personnel
 HSMN NewsFeed - 17 Apr 2013
VentriPoint Receives CE Mark for Major Expansion of Its VMST Platform for Right Heart Analysis
Devices Cardiology Regulatory
 HSMN NewsFeed - 11 Feb 2013
Bayer Submits New Drug Application for Riociguat for the Treatment of Pulmonary Arterial Hypertension and Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 22 Oct 2012
Bayer's Investigational Riociguat Meets Primary Endpoint in Phase III Study in Patients with Pulmonary Arterial Hypertension (PAH)
Biopharmaceuticals
 HSMN NewsFeed - 21 Sep 2012
Cialis(R) (tadalafil) Tablets Recommended for Approval for the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia in the European Union
Biopharmaceuticals Urology Regulatory
 HSMN NewsFeed - 20 Jul 2012
Onyx Pharmaceuticals Receives FDA Accelerated Approval of Kyprolis(TM) (carfilzomib) for Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Jun 2012
Actelion Pharmaceuticals Announces U.S. Food and Drug Administration Approval of Supplemental New Drug Application for Second Generation VELETRI(R) (epoprostenol) for Injection
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 May 2012
Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Feb 2012
Auxilium Pharmaceuticals, Inc. and Actelion Pharmaceuticals Ltd. Enter a Collaboration Agreement for XIAFLEX(R) in Canada, Australia, Brazil and Mexico
Biopharmaceuticals
 HSMN NewsFeed - 16 Feb 2012
Adeona Becomes Synthetic Biologics, Inc.
Biopharmaceuticals
 HSMN NewsFeed - 7 Feb 2012
New Study Evaluates Cialis(R) in parallel with Tamsulosin in Men with Signs and Symptoms Suggestive of Benign Prostatic Hyperplasia
Biopharmaceuticals Urology
 HSMN NewsFeed - 7 Oct 2011
Cialis(R) for Once Daily Use Now FDA-Approved to Treat Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) and Men With Both Erectile Dysfunction (ED) and Signs and Symptoms of BPH
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Aug 2011
FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 5 May 2011
The European Commission Approves Pfizer’s Revatio(R) (sildenafil) for the Treatment of Pulmonary Arterial Hypertension in Children
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 Mar 2011
Lithera Announces the Appointment of George W. Mahaffey as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Dec 2010
Pfizer Stops Clinical Trials of Thelin(R) and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety
Biopharmaceuticals
 HSMN NewsFeed - 25 Aug 2010
Actelion Pharmaceuticals Announces FDA Approval of Brand Name for Commercially Available VELETRI(R) (epoprostenol for injection) for Pulmonary Arterial Hypertension
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Jul 2010
Abbott's PROGRESS Study of Kaletra and Isentress Compared with a Standard HIV Regimen Meets the Pre-Specified Primary Efficacy Endpoint
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 12 May 2010
Pfizer Enters Into Agreement With Ergonex Pharma to Acquire Investigational Treatment for Pulmonary Arterial Hypertension
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 28 Apr 2010
Abbott Receives FDA Approval for Once-Daily Dosing of Kaletra(R) (lopinavir / ritonavir) for Treatment-Experienced Patients
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 22 Apr 2010
Actelion Pharmaceuticals Announces Commercial Availability of Epoprostenol for Injection for the Treatment of Pulmonary Arterial Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 9 Mar 2010
FDA Clears GeNO LLC Investigational New Drug Application for Nitric Oxide Delivery System
Devices Drug Delivery
 HSMN NewsFeed - 19 Feb 2010
United Therapeutics Corporation Withdraws European Marketing Authorization Application for Tyvaso for the Treatment of Pulmonary Arterial Hypertension
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 11 Feb 2010
Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 4 Jan 2010
European Commission Approves New Intravenous Formulation Of Pfizer's Revatio(R) (Sildenafil) For The Treatment Of Pulmonary Arterial Hypertension
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 20 Nov 2009
FDA Approves Intravenous Formulation Of Pfizer's Revatio(R) (Sildenafil) For The Treatment Of Pulmonary Arterial Hypertension
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Oct 2009
Arginetix Closes $10.75 Million Series A Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 26 May 2009
FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Nov 2008
Lilly Licenses U.S. Rights for Tadalafil PAH Indication to United Therapeutics
Biopharmaceuticals Licensing
 HSMN NewsFeed - 17 Nov 2008
FREEDOM-C Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Fails to Meet Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 28 Oct 2008
Gilead Announces Two-Year Clinical Data for Letairis(R) (ambrisentan) for the Treatment of Pulmonary Arterial Hypertension (WHO Group 1)
Biopharmaceuticals
 HSMN NewsFeed - 30 Jun 2008
New Drug Application for Inhaled Treprostinil Submitted to the U.S. Food and Drug Administration
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 20 Jun 2008
Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
Biopharmaceuticals
 HSMN NewsFeed - 29 May 2008
Gilead and Navitas Announce Agreement for Cicletanine for the Treatment of Pulmonary Arterial Hypertension
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 29 May 2008
Data from Pivotal Phase III Studies of Gilead's Letairis(R) (ambrisentan) for Pulmonary Arterial Hypertension (WHO Group 1) in Patients with WHO Functional Class II or III Symptoms Published in Circulation
Biopharmaceuticals
 HSMN NewsFeed - 15 May 2008
Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Feb 2008
Pfizer to Acquire Encysive Pharmaceuticals
Biopharmacetuicals Mergers & Acquisitions
 HSMN NewsFeed - 31 Jan 2008
Encysive Pharmaceuticals Launches THELIN (Sitaxentan Sodium) in Sweden
Biopharmaceuticals
 HSMN NewsFeed - 14 Jan 2008
Encysive Pharmaceuticals Launches THELIN (sitaxentan sodium) in Belgium and Luxembourg
Biopharmaceuticals
 HSMN NewsFeed - 17 Dec 2007
Actelion Provides Update On Bosentan in Metastatic Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Nov 2007
Encysive Pharmaceuticals Launches Thelin (sitaxentan sodium) in Italy
Biopharmaceuticals
 HSMN NewsFeed - 12 Nov 2007
Actelion: Pivlaz (Clazosentan) Phase III Study Initiated to Demonstrate Prevention of Vasospasm-Related Morbidity and All-Cause Mortality After Aneurysmal Subarachnoid Hemorrhage
Biopharmaceuticals Neurosurgery
 HSMN NewsFeed - 1 Nov 2007
Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 24 Oct 2007
Encysive Pharmaceuticals Announces Long-Term Study of Sitaxsentan Presented At Chest Meeting
Biopharmaceuticals
 HSMN NewsFeed - 23 Oct 2007
Tracleer(R) Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 23 Oct 2007
Gilead Announces New LetairisTM (ambrisentan) Data for the Treatment of Patients with Pulmonary Arterial Hypertension (WHO Group 1)
Biopharmaceuticals
 HSMN NewsFeed - 19 Oct 2007
Actelion Ltd: Miglustat (Zavesca) Receives Negative Opinion From the European Committee For Medicinal Products For Human Use For Extension of Indication For Niemann Pick Type C
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 15 Oct 2007
Dong-A PharmTech Signs Licensing Deal With Otechestvennye to Market Zydena in Russia
Biopharmaceuticals Licensing
 HSMN NewsFeed - 24 Sep 2007
Encysive Pharmaceuticals to Conduct Phase III Study With Thelin (Sitaxsentan Sodium) in Pulmonary Arterial Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 13 Sep 2007
Encysive Pharmaceuticals Announces Launch of THELIN (sitaxentan sodium) in Spain
Biopharmaceuticals
 HSMN NewsFeed - 5 Sep 2007
Encysive Pharmaceuticals Receives Written Response From FDA On Its Request for Formal Dispute Resolution for THELIN (Sitaxsentan Sodium)
Biopharmaceuticals
 HSMN NewsFeed - 2 Sep 2007
New Data On Orexin Receptor Antagonist Almorexant Shows Therapeutic Potential to Restore Normal Physiological Sleep in Patients Suffering From Insomnia
Biopharmaceuticals
 HSMN NewsFeed - 14 Aug 2007
Phase II Clinical Trial Results for ADENTRI Published in Journal of the American College of Cardiology
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 10 Aug 2007
Teva Announces Tentative Approval of Sildenafil Citrate Tablets, 20 mg
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 6 Aug 2007
Encysive Pharmaceuticals Files Request for Formal Dispute Resolution With U.S. FDA
Biopharmaceuticals
 HSMN NewsFeed - 13 Jul 2007
Encysive Pharmaceuticals Provides Update for Thelin (Sitaxsentan Sodium)
Biopharmaceuticals
 HSMN NewsFeed - 15 Jun 2007
FDA Issues Third Approvable Letter for Thelin (Sitaxsentan Sodium)
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Jun 2007
U.S. Food and Drug Administration Approves Gilead's Letairis(TM) (ambrisentan) 5 mg and 10 mg Tablets for the Once-Daily Treatment of Pulmonary Arterial Hypertension (WHO Group 1) in Patients with WHO Functional Class II or III Symptoms
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Jun 2007
Bosentan (Tracleer) Receives EU Approval for Reduction of Number of New Digital Ulcerations in Systemic Sclerosis Patients
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 30 May 2007
Canadian Health Authority Approves THELIN (Sitaxsentan Sodium) for Pulmonary Arterial Hypertension
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 May 2007
Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 16 Apr 2007
Encysive Pharmaceuticals Announces Launch of THELIN (Sitaxentan Sodium) in the Netherlands
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 2 Apr 2007
Encysive Pharmaceuticals Announces Launch of Thelin (Sitaxentan Sodium) in Republic of Ireland
Biopharmaceuticals
 HSMN NewsFeed - 29 Mar 2007
Proteo, Inc./Proteo Biotech AG: European Commission grants Orphan Drug Status to Elafin for the treatment of PAH
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Mar 2007
United Therapeutics and Mochida Pharmaceutical Sign Remodulin Distribution Agreement for Japan
Biopharmaceuticals Distribution
 HSMN NewsFeed - 26 Mar 2007
Bosentan -- Tracleer -- Receives Positive EU Opinion for Reduction of New Digital Ulcerations in Systemic Sclerosis Patients
Biopharmaceuticals
 HSMN NewsFeed - 5 Mar 2007
Actelion: Positive Study With Bosentan (Tracleer) in CTEPH
Biopharmaceuticals
 HSMN NewsFeed - 26 Feb 2007
United Therapeutics Announces Pulmonary Hypertension Opinion Leaders' Guidance On Intravenous Therapies
Biopharmaceuticals
 HSMN NewsFeed - 13 Feb 2007
Pfizer's Maraviroc to Receive Accelerated Regulatory Reviews in the U.S. and Europe
Biopharmaceuticals Regulatory HIV/AIDS
 HSMN NewsFeed - 8 Feb 2007
Results of Inhaled Treprostinil Controlled Pilot Studies Reported in the Journal of the American College Of Cardiology
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 5 Feb 2007
Successful Proof-of-Concept With Actelion's Orexin Receptor Antagonist in Patients Suffering From Primary Insomnia -- First Demonstration of Key Role of Orexin System in Humans Suffering From Sleep Disorders
Biopharmaceuticals
 HSMN NewsFeed - 18 Dec 2006
Gilead Submits New Drug Application To U.S. FDA for Ambrisentan for the Treatment of Pulmonary Arterial Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 18 Dec 2006
ICOS Announces Revised Merger Agreement With Lilly
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 18 Dec 2006
Successful Study With Tracleer(r) in Patients With Mildly Symptomatic Pulmonary Arterial Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 12 Dec 2006
United Therapeutics Affiliate Initiates First-Ever Gene-Therapy Trial for Pulmonary Arterial Hypertension
Biopharmaceuticals Regenerative Medicine
 HSMN NewsFeed - 12 Dec 2006
Northern Therapeutics and MaxCyte Initiate Landmark Engineered Cell Therapy Trial for Fatal Lung Disease
Biopharmaceuticals Regenerative Medicine
 HSMN NewsFeed - 11 Dec 2006
Actelion-1 -- First Tissue-Targeting Endothelin Receptor Antagonist -- in Phase III for Pulmonary Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 8 Dec 2006
Actelion Ltd. Announces Commencement of Cash Tender Offer for CoTherix, Inc. and HSR Clearance to Acquire CoTherix, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 20 Nov 2006
Actelion Announces Definitive Agreement to Acquire U.S.-Based CoTherix, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 17 Oct 2006
ICOS Corporation Announces Agreement to be Acquired by Eli Lilly and Company
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 9 Oct 2006
Actelion Ltd: Detailed Analysis of CONSCIOUS-1 Presented at CNS
Biopharmaceuticals Neurosurgery
 HSMN NewsFeed - 2 Oct 2006
Gilead Sciences to Acquire Myogen, Inc. for $2.5 Billion
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 14 Sep 2006
Biogen Idec and mondoBIOTECH Sign Collaboration and Licensing Agreement to Develop and Commercialize Aviptadil for Pulmonary Arterial Hypertension
Biopharmaceuticals Licensing
 HSMN NewsFeed - 7 Sep 2006
Myogen Initiates Open-Label Phase 3 Clinical Trial of Ambrisentan in Patients with Pulmonary Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 28 Jun 2006
CoTherix Licenses Exclusive Rights to Develop and Commercialize Oral and Inhaled Formulations of Fasudil for the Treatment of PAH and Stable Angina in North America and Europe From Asahi Kasei Pharma
Biopharmaceuticals Licensing
 HSMN NewsFeed - 2 Jun 2006
Encysive Pharmaceuticals' Thelin(TM) (sitaxentan sodium) Receives Positive Opinion From European Authorities
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 25 May 2006
Encysive Pharmaceuticals Submits Complete Response to FDA for Thelin(TM) New Drug Application
Biopharmaceuticals
 HSMN NewsFeed - 24 May 2006
Ambrisentan Phase 3 ARIES-2 PAH Data Presented At ATS 2006 -- San Diego
Biopharmaceuticals
 HSMN NewsFeed - 23 May 2006
Actelion: ATS Presentation Highlights Strong Rationale for a Morbidity/Mortality Study with Bosentan in Idiopathic Pulmonary Fibrosis
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 114

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 114 additional stories matching:
pulmonary arterial hypertension
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.